`Patent 9,095,559 B2
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`___________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`___________________
`
`
`
`LUPIN LTD. and LUPIN PHARMACEUTICALS, INC.
`Petitioner,
`
`v.
`
`HORIZON THERAPEUTICS, INC.
`Patent Owner
`
`
`
`Case IPR2016-00829
`Patent 9,095,559 B2
`
`
`
`PETITIONERS’ OBJECTIONS TO EVIDENCE
`PURSUANT TO 37 C.F.R. § 42.64
`
`
`
`
`
`Mail Stop PATENT BOARD
`Patent Trial and Appeal Board
`United States Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`
`
`
`
`
`
`Petitioners Lupin Ltd. and Lupin Pharmaceuticals, Inc. (“Lupin”) hereby
`
`Case IPR2016-00829
`Patent 9,095,559 B2
`
`object pursuant to 37 C.F.R. § 42.64(b)(1) and the Federal Rules of Evidence
`
`(“FRE”) to the admissibility of certain purported evidence served by Patent
`
`Owner’s Horizon Therapeutics, Inc. on February 10, 2017 in connection with its
`
`Response to Lupin’s Petition for Inter Partes Review of U.S. Patent No. 9,095,559
`
`(“the ’559 patent”). The exhibits objected to, and grounds for Lupin’s objections,
`
`are listed below. Lupin also objects to Patent Owner’s reliance on or citations to
`
`any objected evidence in its papers.
`
`Some of the exhibits served by Horizon Therapeutics, Inc. on February 10,
`
`2016 were introduced during the deposition of Keith Vaux in this proceeding, and
`
`Lupin objected to those exhibits at the deposition as required by 37 C.F.R. §
`
`42.64(a). Nothing contained herein shall be deemed to withdraw any of Lupin’s
`
`objections to deposition evidence or the requirement that evidence to cure those
`
`objections must have been provided during the deposition.
`
`I.
`
`IDENTIFICATION OF CHALLENGED EVIDENCE AND GROUNDS
`FOR OBJECTIONS
`A. Exhibit 2001
`Lupin objects to Exhibit 2001 under FRE 402 and 403 because it is
`
`irrelevant and its probative value is substantially outweighed by the danger of
`
`wasting time in this compressed proceeding. Exhibit 2001 is a litigation document
`
`which bears no relevance to the issue of patentability of the ’559 patent claims.
`
`
`
`- 2 -
`
`
`
`
`Lupin further objects to Exhibit 2001 under FRE 802 because it is inadmissible
`
`Case IPR2016-00829
`Patent 9,095,559 B2
`
`hearsay, specifically a complaint in a district court litigation, Horizon
`
`Therapeutics, Inc. v. Lupin Ltd., 1:15-cv-07624-RBK-JS (D.N.J.). Lupin also
`
`objects to Exhibit 2001 under FRE 901 on the basis that it has not been properly
`
`authenticated and lacks foundation.
`
`Exhibit 2002
`
`B.
`Lupin objects to Exhibit 2002 under FRE 402 and 403 because it is
`
`irrelevant and its probative value is substantially outweighed by the danger of
`
`wasting time in this compressed proceeding. Exhibit 2002 is a litigation document
`
`which bears no relevance to the issue of patentability of the ’559 patent claims.
`
`Lupin further objects to Exhibit 2002 under FRE 802 because it is inadmissible
`
`hearsay, specifically an amended complaint in a district court litigation, Horizon
`
`Therapeutics, Inc. v. Lupin Ltd., 1:15-cv-07624-RBK-JS (D.N.J.). Lupin also
`
`objects to Exhibit 2002 under FRE 901 on the basis that it has not been properly
`
`authenticated and lacks foundation.
`
`C. Exhibit 2003
`Lupin objects to Exhibit 2003 as incomplete. It should therefore be
`
`excluded under FRE 106 and 403.
`
`
`
`- 3 -
`
`
`
`
`
`D. Exhibit 2004
`Lupin objects to Exhibit 2004 as incomplete. It should therefore be
`
`Case IPR2016-00829
`Patent 9,095,559 B2
`
`excluded under FRE 106 and 403.
`
`Exhibit 2005
`
`E.
`Lupin objects to Exhibit 2005 under FRE 402 and 403 because it is
`
`irrelevant and its probative value is substantially outweighed by the danger of
`
`wasting time in this compressed proceeding. Exhibit 2005 is a litigation document
`
`served by Par Pharmaceuticals, Inc. in a different proceeding regarding different
`
`patents, and therefore bears no relevance to the issue of patentability of the ’559
`
`patent claims. Lupin further objects to Exhibit 2005 under FRE 802 because it is
`
`inadmissible hearsay, specifically a non-party’s invalidity and non-infringement
`
`contentions in an unrelated district court litigation, Horizon Therapeutics, Inc. v.
`
`Par Pharmaceuticals, Inc., C.A. No. 2:14-cv-00384-JRG-RSP (E.D. Tex). Lupin
`
`also objects to Exhibit 2005 under FRE 901 on the basis that it has not been
`
`properly authenticated and lacks foundation. Lupin further objects to Exhibit 2005
`
`as incomplete because it contains only certain portions of Par Pharmaceutical’s
`
`Invalidity and Non-infringement Contentions, and should therefore be excluded
`
`under FRE 106.
`
`
`
`- 4 -
`
`
`
`
`
`Exhibit 2006
`
`F.
`Lupin objects to Exhibit 2006, the declaration of Dr. Gregory M. Enns,
`
`Case IPR2016-00829
`Patent 9,095,559 B2
`
`under FRE 402 to the extent that it includes or relies on irrelevant or inadmissible
`
`information and under FRE 403 to the extent that it includes or relies on
`
`information that probative value of which is substantially outweighed by the
`
`danger of unfair prejudice, wasting time, or needlessly presenting cumulative
`
`evidence as set forth herein. Lupin further objects to Exhibit 2006 under FRE 901
`
`on the basis that it cites or relies on exhibits that have not been properly
`
`authenticated or lack foundation, as set forth herein.
`
`G. Exhibit 2012
`Lupin objects to Exhibit 2012 under FRE 402 and 403 because it is
`
`irrelevant and its probative value is substantially outweighed by the danger of
`
`wasting time in this compressed proceeding. Exhibit 2012 was published in 2012
`
`and, therefore, bears no relevance to what the person of ordinary skill in the art
`
`would have known by the relevant date, Sept. 30, 2011. Therefore, Exhibit 2012
`
`should be excluded under FRE 402 and 403. Lupin further objects to Exhibit 2012
`
`under FRE 802 on the basis that it is inadmissible hearsay, not within a hearsay
`
`exception.
`
`
`
`- 5 -
`
`
`
`
`
`H. Exhibit 2015
`Lupin objects to Exhibit 2015 under FRE 402 and 403 because it is
`
`Case IPR2016-00829
`Patent 9,095,559 B2
`
`irrelevant and its probative value is substantially outweighed by the danger of
`
`wasting time in this compressed proceeding. Exhibit 2015 is dated after September
`
`30, 2011, and therefore bears no relevance to what the person of ordinary skill in
`
`the art would have known by the relevant date. Therefore, Exhibit 2015 should be
`
`excluded under FRE 402 and 403. Lupin further objects to Exhibit 2015 under
`
`FRE 802 on the basis that it is inadmissible hearsay, not within a hearsay
`
`exception.
`
`Exhibit 2019
`
`I.
`Lupin objects to Exhibit 2019 under FRE 402 and 403 because it is
`
`irrelevant and its probative value is substantially outweighed by the danger of
`
`wasting time in this compressed proceeding. Exhibit 2019 is dated after September
`
`30, 2011, and therefore bears no relevance to what the person of ordinary skill in
`
`the art would have known by the relevant date. Therefore, Exhibit 2019 should be
`
`excluded under FRE 402 and 403. Lupin further objects to Exhibit 2019 under
`
`FRE 802 on the basis that it is inadmissible hearsay, not within a hearsay
`
`exception.
`
`
`
`- 6 -
`
`
`
`
`
`Exhibit 2026
`
`J.
`Lupin objects to Exhibit 2026 under FRE 402 and 403 because it is
`
`Case IPR2016-00829
`Patent 9,095,559 B2
`
`irrelevant and its probative value is substantially outweighed by the danger of
`
`wasting time in this compressed proceeding. Exhibit 2026 is dated after September
`
`30, 2011, and therefore bears no relevance to what the person of ordinary skill in
`
`the art would have known by the relevant date. Therefore, Exhibit 2026 should be
`
`excluded under FRE 402 and 403. Lupin further objects to Exhibit 2026 under
`
`FRE 802 on the basis that it is inadmissible hearsay, not within a hearsay
`
`exception. Lupin also objects to Exhibit 2026 under FRE 901 on the basis that it
`
`has not been properly authenticated and lacks foundation.
`
`K. Exhibit 2027
`Lupin objects to Exhibit 2027 under FRE 402 and 403 because it is
`
`irrelevant and its probative value is substantially outweighed by the danger of
`
`wasting time in this compressed proceeding. Exhibit 2027 does not have a
`
`discernible publication date and Patent Owner has not established that it is prior
`
`art. Absent such a showing, it bears no relevance to what the person of ordinary
`
`skill in the art would have known by the relevant date, Sept. 30, 2011. Therefore,
`
`Exhibit 2027 should be excluded under FRE 402 and 403. Lupin further objects to
`
`Exhibit 2027 under FRE 802 on the basis that it is inadmissible hearsay, not within
`
`
`
`- 7 -
`
`
`
`
`a hearsay exception. Lupin also objects to Exhibit 2027 under FRE 901 on the
`
`Case IPR2016-00829
`Patent 9,095,559 B2
`
`basis that it has not been properly authenticated and lacks foundation.
`
`Exhibit 2029
`
`L.
`Lupin objects to Exhibit 2029 under FRE 402 and 403 because it is
`
`irrelevant and its probative value is substantially outweighed by the danger of
`
`wasting time in this compressed proceeding. Exhibit 2029 is dated after September
`
`30, 2011, and therefore bears no relevance to what the person of ordinary skill in
`
`the art would have known by the relevant date. Therefore, Exhibit 2026 should be
`
`excluded under FRE 402 and 403. Lupin further objects to Exhibit 2026 under
`
`FRE 802 on the basis that it is inadmissible hearsay, not within a hearsay
`
`exception.
`
`M. Exhibit 2033
`Lupin objects to Exhibit 2033 under FRE 402 and 403 because it is
`
`irrelevant and its probative value is substantially outweighed by the danger of
`
`wasting time in this compressed proceeding. Exhibit 2033 does not have a
`
`discernible publication date and Patent Owner has not established that it is prior
`
`art. Absent such a showing, it bears no relevance to what the person of ordinary
`
`skill in the art would have known by the relevant date, Sept. 30, 2011. Therefore,
`
`Exhibit 2033 should be excluded under FRE 402 and 403. Lupin further objects to
`
`
`
`- 8 -
`
`
`
`
`Exhibit 2033 under FRE 802 on the basis that it is inadmissible hearsay, not within
`
`Case IPR2016-00829
`Patent 9,095,559 B2
`
`a hearsay exception. Lupin also objects to Exhibit 2033 under FRE 901, 1002 and
`
`1003 on the basis that it has not been properly authenticated and lacks foundation.
`
`N. Exhibit 2034
`Lupin objects to Exhibit 2034 as incomplete to the extent that it does not
`
`include errata. It should therefore be excluded under FRE 106 and 403.
`
`O. Exhibit 2035
`Lupin objects to Exhibit 2035 under FRE 402 and 403 because it is
`
`irrelevant and its probative value is substantially outweighed by the danger of
`
`wasting time in this compressed proceeding. Exhibit 2035 has no discernible
`
`publication date and Patent Owner has not established that it is prior art. Absent
`
`such a showing, it bears no relevance to what the person of ordinary skill in the art
`
`would have known by the relevant date, Sept. 30, 2011. Therefore, Exhibit 2035
`
`should be excluded under FRE 402 and 403. Lupin further objects to Exhibit 2035
`
`under FRE 802 on the basis that it is inadmissible hearsay, not within a hearsay
`
`exception. Lupin also objects to Exhibit 2035 under FRE 901 on the basis that it
`
`has not been properly authenticated and lacks foundation.
`
`- 9 -
`
`
`
`
`
`
`
`
`
`Exhibit 2036
`
`P.
`Lupin objects to Exhibit 2036 under FRE 402 and 403 because it is
`
`Case IPR2016-00829
`Patent 9,095,559 B2
`
`irrelevant and its probative value is substantially outweighed by the danger of
`
`wasting time in this compressed proceeding. Lupin also objects to Exhibit 2036
`
`under FRE 901, 1002 and 1003 on the basis that it has not been properly
`
`authenticated and lacks foundation.
`
`Q. Exhibit 2037
`Lupin objects to Exhibit 2037 under FRE 402 and 403 because it is
`
`irrelevant and its probative value is substantially outweighed by the danger of
`
`wasting time in this compressed proceeding. Lupin also objects to Exhibit 2037
`
`under FRE 901 on the basis that it has not been properly authenticated and lacks
`
`foundation.
`
`R. Exhibit 2038
`Lupin objects to Exhibit 2038 under FRE 402 and 403 because it is
`
`irrelevant and its probative value is substantially outweighed by the danger of
`
`wasting time in this compressed proceeding. Exhibit 2038 does not have a
`
`discernible publication date and Patent Owner has not established that it is prior
`
`art. Absent such a showing, it bears no relevance to what the person of ordinary
`
`skill in the art would have known by the relevant date, Sept. 30, 2011. Therefore,
`
`Exhibit 2038 should be excluded under FRE 402 and 403. Lupin further objects to
`
`
`
`- 10 -
`
`
`
`
`Exhibit 2038 under FRE 802 on the basis that it is inadmissible hearsay, not within
`
`Case IPR2016-00829
`Patent 9,095,559 B2
`
`a hearsay exception. Lupin also objects to Exhibit 2038 under FRE 901 on the
`
`basis that it has not been properly authenticated and lacks foundation.
`
`Exhibit 2041
`
`S.
`Lupin objects to Exhibit 2041 under FRE 402 and 403 because it is
`
`irrelevant and its probative value is substantially outweighed by the danger of
`
`wasting time in this compressed proceeding. Exhibit 2041 is dated after September
`
`30, 2011, and therefore bears no relevance to what the person of ordinary skill in
`
`the art would have known by the relevant date. Therefore, Exhibit 2041 should be
`
`excluded under FRE 402 and 403. Lupin further objects to Exhibit 2041 under
`
`FRE 802 on the basis that it is inadmissible hearsay, not within a hearsay
`
`exception. Lupin also objects to Exhibit 2041 under FRE 901 on the basis that it
`
`has not been properly authenticated and lacks foundation.
`
`Exhibit 2042
`
`T.
`Lupin objects to Exhibit 2042 under FRE 402 and 403 because it is
`
`irrelevant and its probative value is substantially outweighed by the danger of
`
`wasting time in this compressed proceeding. Exhibit 2042 is dated after September
`
`30, 2011, and therefore bears no relevance to what the person of ordinary skill in
`
`the art would have known by the relevant date. Therefore, Exhibit 2042 should be
`
`
`
`- 11 -
`
`
`
`
`excluded under FRE 402 and 403. Lupin further objects to Exhibit 2042 under
`
`Case IPR2016-00829
`Patent 9,095,559 B2
`
`FRE 802 on the basis that it is inadmissible hearsay, not within a hearsay
`
`exception.
`
`U. Exhibit 2045
`Lupin objects to Exhibit 2045 under FRE 402 and 403 because it is
`
`irrelevant and its probative value is substantially outweighed by the danger of
`
`wasting time in this compressed proceeding. Exhibit 2045 has no discernible
`
`publication date and Patent Owner has not established that it is prior art. Absent
`
`such a showing, it bears no relevance to what the person of ordinary skill in the art
`
`would have known by the relevant date, Sept. 30, 2011. Therefore, Exhibit 2045
`
`should be excluded under FRE 402 and 403. Lupin further objects to Exhibit 2045
`
`under FRE 802 on the basis that it is inadmissible hearsay, not within a hearsay
`
`exception. Lupin also objects to Exhibit 2045 under FRE 901 on the basis that it
`
`has not been properly authenticated and lacks foundation.
`
`- 12 -
`
`
`
`
`
`
`
`Case IPR2016-00829
`Patent 9,095,559 B2
`
`Respectfully submitted,
`
`/Cynthia Lambert Hardman/
`Elizabeth J. Holland (Reg. No. 47,657)
`Cynthia Lambert Hardman (Reg. No.
`53,179)
`GOODWIN PROCTER LLP
`The New York Times Building
`620 Eighth Avenue
`New York, NY 10018
`(212) 813-8800 (telephone)
`(212) 355-3333 (facsimile)
`
`Counsel for Petitioners
`
`
`
`
`
`
`
`
`Dated: February 17, 2016
`
`
`
`- 13 -
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`Case IPR2016-00829
`Patent 9,095,559 B2
`
`The undersigned hereby certifies that PETITIONERS’ OBJECTIONS TO
`
`EVIDENCE PURSUANT TO 37 C.F.R. 42.64 was served electronically via email
`
`on February 17, 2017 on the following:
`
`James B. Monroe (lead counsel, Reg. No. 33,971)
`Maureen D. Queler (backup counsel, Reg. No. 61,879)
`FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP
`James.monroe@finnegan.com
`Maureen.queler@finnegan.com
`
`
`
`Matthew Phillips (backup counsel, Reg. No. 43,403)
`Renaissance IP Law Group LLP
`matthew.phillips@renaissanceiplaw.com
`
`
`
`Robert Green (Reg. No. 27,555)
`Emer Simic (Reg. No. 61,235)
`Green, Griffith & Borg-Breen, LLP
`rgreen@greengriffith.com
`esimic@greengriffith.com
`
`Dated: February 17, 2017
`
`
`
`/Cynthia Lambert Hardman/
`Cynthia Lambert Hardman
`
`
`
`- 14 -
`
`
`